How to evaluate neurology and stroke AI
Neurology AI ranges from software that flags a large-vessel occlusion on CT and alerts the stroke team, to EEG analysis and brain MRI measurements used in dementia care. Each needs different evidence.
Use the section that matches the tool. The questions in the core guide apply to all of them.
Last reviewed November 2026 · Independent and vendor-neutral
What does the tool you’re evaluating do?
Jump to the matching checklist. Some answers lead to a different guide.
Stroke detection and care coordination
Applies if the tool flags large-vessel occlusion, bleeding or perfusion deficits on imaging, or coordinates the stroke team and transfers.
Questions to ask
- What are sensitivity and false-alert rates for each finding, and at which hospitals and scanners were they measured?
- How long from scan to alert, and does the neurointerventional team actually use the mobile viewer?
- How does it work for spoke hospitals that transfer patients to your hub?
- If you expect add-on payment: CMS granted the first AI new-technology add-on payment (NTAP) for stroke triage in 2020. NTAP is time-limited, so confirm current payment before counting on it.
Measure
- Door-to-needle, door-to-groin and transfer times for 6 months before and after go-live
- Audit of missed occlusions
Red flags
- Time savings claimed only from single-site retrospective data
- No workflow for spoke hospitals
The radiology guide covers imaging triage tools in more depth, including worklist effects and false-positive workload. Read that guide →
EEG analysis
Applies if the tool reads EEG, for example to detect seizures or spikes, in the ICU, emergency department or epilepsy unit.
Questions to ask
- Which functions are FDA-cleared and which are research-only?
- How does it perform on your EEG hardware and montages, and in noisy ICU recordings?
- Who reviews detections, and how quickly, especially overnight?
Red flags
- Unclear line between cleared and research features
- No reviewer workflow for alerts
Brain MRI measurement and dementia care
Applies if the tool measures brain volumes or lesions on MRI, for example to support dementia diagnosis, multiple sclerosis follow-up or monitoring for side effects of anti-amyloid therapy.
Questions to ask
- Which scanners, field strengths and sequences is it validated on? Will changing scanners change the results?
- How are results reviewed by a radiologist before they reach the clinician?
- For anti-amyloid therapy monitoring, how does it support detection of ARIA, and what is the miss rate?
Red flags
- No data on scanner-to-scanner consistency
- Results reported without radiologist review
Further reading
Browse neurology tools
Every listing shows regulatory status, published evidence and named health-system users where public.